 |
 |
Phoenix Pharmaceuticals, Inc.
|
 |
肾上腺髓质素2 / Intermedin (中介素或介质素)
A new peptide of Calcitonin/CGRP family reduces blood pressure, induces
antidiuresis and antinatriuresis , enables food intake suppression
as well as induce gastric emptying activity.
一个降钙素和降钙素基因相关肽家族的新成员, 不仅可以降低动脉的血压,抑制食物的摄取和胃排空的活动,
还具有抗利钠利尿的作用.
中介素是美国斯坦福大学妇产科研究所许教授在2003年11月研究报告的一种47个氨基酸组成的心血管多肽和脑肠肽, 可以促进细胞内cAMP水平的升高,
显著降低正常对照和自发性高血压大鼠的动脉收缩压, 升高心率; 抑制动物的食物摄取量和胃排空. 中介素主要在胃肠组织有高表达, 在脑垂体也有其免疫活性.中介素可以结合CGRP和ADM的受体以及RAMPs复合体.
最近, 日本学者报告一个新发现的肾上腺髓质素2, 与美国斯坦福大学发表的中介素的氨基酸序列完全相同. AM2的基因主要表达在颌下腺,
肾脏, 胃, 肠系膜上动脉, 卵巢, 淋巴结, 胰腺等组织中. 它的降血压的作用明显强于已知的肾上腺髓质素, 而且, AM2还有抗利钠利尿的作用.推测中介素可能对研究心血管疾病,胃肠功能紊乱以及体内能量稳态失平衡所致的肥胖具有重要病理生理学意义.康肽生物和美国凤凰药物是目前国际上第一家商业化提供中介素,中介素拮抗剂以及各种标记的中介素衍生物的生物高科技公司.
康肽生物和美国凤凰药物即将启动与美国Temple大学医学院药理学系以及北京大学医学中心生理系开展INTERMEDIN的基础协作研究
(美国凤凰药物有限公司, 康肽生物科技(北京)有限公司, 杨军, 总结于2003年11月24日,并更新于2004年元月26日于旧金山湾区).
|
Intermedin is a calcitonin/CGRP family peptide acting through the
CRLR/RAMP receptor complexes |
| Calcitonin, calcitonin gene-related
peptide (CGRP), adrenomedullin (ADM), and amylin belong
to a unique group of peptide hormones important for homeostasis
in diverse tissues. Calcitonin is essential for calcium
balance whereas CGRP and ADM are important for neurotransmission,
and cardiovascular and respiratory regulation. Based on
phylogenetic analysis, we identified intermedin as a novel
member of the calcitonin/CGRP peptide family. Analysis of
intermedin expression indicated that intermedin is expressed
primarily in the pituitary and gastrointestinal tract. Intermedin
increases cAMP production in SK-N-MC and L6 cells expressing
endogenous CGRP receptors and competes with labeled CGRP
for binding to its receptors in these cells. In addition,
treatment of 293T cells expressing recombinant calcitonin
receptor-like receptor (CRLR) and one of the three receptor
activity modifying proteins (RAMPs) showed that a CRLR/RAMP
receptor complex is required for intermedin signaling. In
contrast to CGRP and ADM, which exhibit a preferential stimulation
of CRLR when coexpressed with RAMP1 and RAMP2 or RAMP3,
respectively, intermedin represents a nonselective agonist
for the RAMP co-receptors. In vivo studies demonstrated
that intermedin treatment leads to blood pressure reduction
in both normal and spontaneously hypertensive rats via interactions
with the CRLR/RAMP receptors. Furthermore, in vivo treatment
in mice with intermedin leads to a suppression of gastric
emptying activity and food intake. Thus, identification
of intermedin as a novel member of the calcitonin/CGRP peptide
family capable of signaling through the CRLR/RAMP receptor
complexes provides an additional player in the regulation
of peripheral tissues by CRLR, and will allow development
of new therapeutic agents for pathologies associated with
diverse vascular and gastrointestinal disorders. |
| Roh
J, Chang CL, Bhalla A, Klein C, Hsu SY. J Biol Chem. 2003
Nov 13 [Epub ahead of print]. |
|
Identification of novel adrenomedullin in mammals: a potent
cardiovascular and renal regulator
|
| We have identified cDNA encoding
a new member of the adrenomedullin (AM) family, AM2, for
the first time in mammals (mouse, rat and human). The predicted
precursor carried mature AM2 in the C-terminus, which had
an intramolecular ring formed by an S朣 bond and a possibly
amidated C-terminus. Phylogenetic analyses clustered AM2
and AM into two distinct but closely related groups. Similarity
of exon杋ntron structure and synteny of neighboring genes
showed that mammalian AM2 is an ortholog of pufferfish AM2
and a paralog of mammalian AM. AM2 mRNA was expressed in
submaxillary gland, kidney, stomach, ovary, lymphoid tissues
and pancreas of mice, but not in adrenal and testis. Intravenous
injection of synthetic mature AM2 decreased arterial pressure
more potently than AM, and induced antidiuresis and antinatriuresis
in mice. These results show that at least two peptides,
AM and AM2, comprise an adrenomedullin family in mammals,
and that AM2 may play pivotal roles in cardiovascular and
body fluid regulation. |
| Takei
Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S. FEBS
Lett. 2004 Jan 2; 556(1-3): 53-8.
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
|
| |
|
|
 |
|
|
|
|
|
 |
|
|
|
|
|

|
|
|
|
|
 |
|

|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

|
| Fig. 1. Amino acid sequences of AMs. a:
Precursor sequences of mouse, rat and human AM2 deduced from
the cloned cDNA. Sequences identical to mouse AM2 are
reversed. Putative signal sequence is underlined [33].
Putative mature peptide is boxed. Accession numbers: mouse
AM2, AB121035; rat AM2, AB101236; human AM2, AB121034.
Asterisks represent stop codons. b: Comparison of mature AM2
and AM/AM1 sequences from mammals and pufferfish. Amino acid
residues identical to the mouse peptide are reversed in each
group. Brackets show disulfide bonds. |
|

|
| Fig. 2. Phylogenetic tree of mouse (m), rat (r),
human (h) and pufferfish (Tr) AM2, AM, CGRP, and/or amylin
depicted by the neighbor-joining method. Precursor sequences
were used for the analysis. Bootstrap values after 1000
trials are indicated on the tree. Accession numbers: mouse
AM, NM_009627; CGRP, AF330212; amylin, NM_010491;
rat AM, NM_012715; CGRP, M11597; amylin, NM_012586;
human AM, NM_001124; CGRP, X02330; amylin, NM_000415;
pufferfish AM1, AB120295; AM2, AB120296; CGRP,
AJ309015. |
|

|
Fig. 3. Structure of AM2 genes. a: Exon杋ntron
structures of mouse, human and pufferfish AM2 and 3 genes.
Exons are shown as boxes. Mature AM sequences are in black,
and coding regions are shadowed. Blank boxes indicate
untranslated sequences. b: Conserved synteny of genes around
the AM2 gene among mouse, human and pufferfish. Arrows
indicate the direction of each gene. A, BC024879 for mouse
and KIAA0685 for human; B, ALDRL6; C, AI451006 for mouse and
BC002942 for human. A and C have different names in mouse
and human but are orthologs.
|
|

|
| Fig. 4. Expression of AM2 and AM genes in
various tissues of male and female mice examined by RT-PCR.
GAPDH is used as an internal control. Similar results were
obtained in two males or two females. |
|

|
Fig. 5. An example of changes in arterial
pressure (AP), heart rate (HR) and urine flow rate after
injection of AM2 at 10 nmol/kg in urethane-anesthetized
mouse. Each spike represents 15 l
of urine dropped from a bladder catheter. Arrows show the
point of injection. |
|

|
| Fig. 6. Comparison of cardiovascular and
renal actions of AM2 and AM in mice (n=4). a:
Dose杛esponse relationship for vasodepressor effects of
AM2 and AM. The difference between the two peptides is
significant as determined by ANOVA. *P<0.05 by
Tukey's test. b: Effects of AM2 (a,b) and AM (c,d) on urine
flow rate and urinary Na+ excretion at 10 nmol/kg.
The decrease in Na+ excretion was more prominent
because of a decrease in urine Na+ concentration.
*P<0.05 compared with the pre-injection value. |
|
|
Intermedin
related products |
|